Mmoncovacs Spółka z Ograniczoną Odpowiedzialnością (KRS 0000845189, NIP 9721308750) is a Polish company, headquartered in Złotniki, Wielkopolskie voivodeship. MMONCOVACS operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since June 8, 2020. MMONCOVACS's most recently reported net revenue was 0 PLN for 2022.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Mmoncovacs
Identity
- Name
- Mmoncovacs Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 8, 2020
- Registry status as of
- November 21, 2025
- Latest entry
- May 24, 2023
- Founding act
- 29.05.2020 R., NOTARIUSZ DOROTA MUSIAŁKIEWICZ, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 6523/2020
Articles of association history (2)
- May 29, 2020: 29.05.2020 R., NOTARIUSZ DOROTA MUSIAŁKIEWICZ, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 6523/2020
- June 15, 2022: 15.06.2022 R., NOTARIUSZ DOROTA MUSIAŁKIEWICZ, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 10443/2022 – ZMIENIONO § 2 UMOWY SPÓŁKI I PRZYJĘTO JEJ TEKST JEDNOLITY.
Activities
Other activities
Address and contact
- Address
- UL. BOLESŁAWA PRUSA, 22, 62-002, ZŁOTNIKI, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.4863, 16.8312approx.
Risk and payment profile - Mmoncovacs
Credibility rating
54.1 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
10
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/6 yrs
Board changes
0
0/6 yrs
PKD changes
0
0/6 yrs
Name changes
1
1/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2021–2022
Current: D (54/100)
Trend: stable (+0.2 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2021–2022
Current: 810 PLN
Safe: 243 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Mmoncovacs
Founded
June 8, 2020
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ZŁOTNIKI
WIELKOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
2 years
2021–2022
Registry entries
13
latest: May 24, 2023
Revenue
0 PLN
2022
Net profit
0 PLN
2022
Assets
5.0 K PLN
2022
Equity
5.0 K PLN
2022
EBITDA
0 PLN
2022
Valuation
4.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Mmoncovacs.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
